Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New hope for high Lp(a)! 💉 Lepodisiran, a long-acting siRNA, slashed Lp(a) by 94% with just 2 shots/year. 🔬 RNA precision meets cardiac prevention. 📉 Silent killer, silenced. #CardioTwitter #RNAtherapy #LipoproteinA
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
🌬️🚶♂️ COPD comes in many forms! From chronic bronchitis 🪫 to emphysema 💨, frequent exacerbators 🚨, asthma-COPD overlap 🌪️, and eosinophilic type 🧫. Tailoring treatment to phenotype is key! #COPD #PrecisionMedicine #RespiratoryCare
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚀 TANDEM Trial: Combining Obicetrapib & Ezetimibe for a powerful LDL reduction! 💊 ✅ -48.6% vs placebo, -27.9% vs Ezetimibe, -16.8% vs Obicetrapib 💪 Safe, effective, and oral! #Cardiology #LipidManagement #ASCVD
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
A gut fungus 🍄 (Fusarium foetens) secretes FF-C1 🧪, a metabolite that inhibits CerS6 and lowers ceramides 🩸—shielding mice from MASH 🛡️. Fungi aren’t just freeloaders—they may be our next therapeutic allies! 💊🧠 #Microbiome #LiverHealth #FungalTherapy #Science
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚀 Obicetrapib: A Breakthrough in LDL Lowering! 📉 Reduced LDL by 29.9% in high-risk patients (p<0.001) 💡 Promising adjunct to lipid-lowering therapy! #Cardiology #LipidManagement #HeartHealth 💓
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
Here’s a tweet with emojis based on the article: 🧬 Middle-age spread decoded! 🕰️ Visceral fat grows in midlife not from bigger cells—but new ones! 🎯 CP-A cells fire up fat formation via LIFR–STAT3 🔥 💊 Targeting them may halt metabolic disease before it starts. #Aging #Obesity #CellBiology #Metabolism 🧫 Would you like a version with a more humorous tone or one tailored for clinicians?
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New era in heart disease prediction! 🧬 + 🧪 + 🤖 = Meta-prediction model that beats PCE & QRISK3 📈 Detects hidden CAD risk in young, women & “low-risk” groups 🎯 Precision prevention just got personal. 🫀 Published in Nature Medicine #CardioTwitter #AI #Genomics #CAD
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
Epicurus (341–270 BC) was an ancient Greek philosopher who founded Epicureanism, emphasizing the pursuit of a tranquil, happy life through ataraxia (freedom from fear) and aponia (absence of pain). His teachings combined atomism, ethics, and naturalistic theology, advocating simple living, friendship, and the rejection of superstition.
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨ECLIPSE Trial Results🚨 Orbital atherectomy 🌀 vs. balloon angioplasty 🎈 before stenting in severe coronary calcification 💔 🎯 No added benefit with atherectomy 🧠 Balloon-first + imaging = smart strategy 📊 Lancet 2025 | #CardioTwitter #InterventionalCardiology #ECLIPSETrial
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
“Your DNA 🧬 is just half the story — your exposome 🌍 writes the rest! From air 🌫️ to food 🍎 to stress 😰, exposomics unlocks the hidden drivers of health 🔍💥. Predict. Prevent. Prosper. 🚀 #Exposomics #PrecisionMedicine”
info_outlineCoronary CT angiography-guided management of patients
with stable chest pain: 10-year outcomes from the SCOT-
HEART randomised controlled trial in Scotland
Michelle C Williams, Ryan Wereski, Christopher Tuck, Philip D Adamson, Anoop S V Shah, Edwin J R van Beek, Giles Roditi, Colin Berry,Nicholas Boon, Marcus Flather, Steff Lewis, John Norrie, Adam D Timmis, Nicholas L Mills, Marc R Dweck, David E Newby, on behalf of theSCOT-HEART Investigators*
Summary
Background The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management
guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with
stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in
management and outcomes.
Methods SCOT-HEART was an open-label, multicentre, parallel group trial for which patients were recruited from
12 outpatient cardiology chest pain clinics across Scotland. Eligible patients were aged 18–75 years with symptoms of
suspected stable angina due to coronary heart disease. Patients were randomly assigned (1:1) to standard of care plus
CCTA or standard of care alone. In this prespecified 10-year analysis, prescribing data, coronary procedural
interventions, and clinical outcomes were obtained through record linkage from national registries. The primary
outcome was coronary heart disease death or non-fatal myocardial infarction on an intention-to-treat basis. This trial
is registered at ClinicalTrials.gov (NCT01149590) and is complete.
Findings Between Nov 18, 2010, and Sept 24, 2014, 4146 patients were recruited (mean age 57 years [SD 10], 2325 [56·1%] male, 1821 [43·9%] female), with 2073 randomly assigned to standard care and CCTA and 2073 to standard care
alone. After a median of 10·0 years (IQR 9·3–11·0), coronary heart disease death or non-fatal myocardial infarction
was less frequent in the CCTA group compared with the standard care group (137 [6·6%] vs 171 [8·2%]; hazard ratio
[HR] 0·79 [95% CI 0·63–0·99], p=0·044). Rates of all-cause, cardiovascular, and coronary heart disease death, and
non-fatal stroke, were similar between the groups (p>0·05 for all), but non-fatal myocardial infarctions (90 [4·3%] vs
124 [6·0%]; HR 0·72 [0·55–0·94], p=0·017) and major adverse cardiovascular events (172 [8·3%] vs 214 [10·3%];
HR 0·80 [0·65–0·97], p=0·026) were less frequent in the CCTA group. Rates of coronary revascularisation procedures
were similar (315 [15·2%] vs 318 [15·3%]; HR 1·00 [0·86–1·17], p=0·99) but preventive therapy prescribing remained
more frequent in the CCTA group (831 [55·9%] of 1486 vs 728 [49·0%] of 1485 patients with available data; odds ratio
1·17 [95% CI 1·01–1·36], p=0·034).
Interpretation After 10 years, CCTA-guided management of patients with stable chest pain was associated with a
sustained reduction in coronary heart disease death or non-fatal myocardial infarction. Identification of coronary
atherosclerosis by CCTA improves long-term cardiovascular disease prevention in patients with stable chest pain.